We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XOMA
176
PUT
DELISTED
Xoma
XOMA
$513K 0.02%
61
+1
+2% +$85
AMPE
177
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$497K 0.02%
469
+311
+197% +$524K
AMPE
178
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$497K 0.02%
5
-1
-17% -$1.68K
EXEL icon
179
CALL
Exelixis
EXEL
$14.1B
$496K 0.02%
3,244
-112
-3% -$359
ALXA
180
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$475K 0.02%
2,040
– –
PGEN icon
181
Precigen
PGEN
$2.51B
$471K 0.02%
+26,507
New +$541K
IRWD icon
182
CALL
Ironwood Pharmaceuticals
IRWD
$671M
$464K 0.02%
+170
New +$1.95K
ARWR icon
183
Arrowhead Research
ARWR
$9.98B
$451K 0.02%
30,513
-141,840
-82% -$1.94M
BSTG
184
DELISTED
Biostage, Inc. Common Stock
BSTG
$451K 0.02%
55,621
+27,891
+101% +$228K
ALTO icon
185
PUT
Alto Ingredients
ALTO
$317M
$443K 0.02%
317
-195
-38% -$3.67K
EXEL icon
186
PUT
Exelixis
EXEL
$14.1B
$438K 0.02%
2,864
+239
+9% +$767
EXEL icon
187
Exelixis
EXEL
$14.1B
$430K 0.02%
281,322
+119,322
+74% +$383K
EXAS
188
DELISTED
Exact Sciences
EXAS
$425K 0.02%
+21,952
New +$402K
CTIC
189
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$420K 0.02%
+174
New +$4.52K
STAB
190
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$404K 0.02%
44,053
+28,745
+188% +$263K
EYPT icon
191
EyePoint Inc
EYPT
$316M
$394K 0.02%
+8,908
New +$401K
EYPT icon
192
PUT
EyePoint Inc
EYPT
$316M
$393K 0.02%
89
– –
ALIM
193
CALL
DELISTED
Alimera Sciences
ALIM
$376K 0.01%
46
-13
-22% -$1.11K
NPSP
194
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$375K 0.01%
14,408
-15,650
-52% -$449K
TNXP icon
195
Tonix Pharmaceuticals
TNXP
$199M
– –
0
– –
KERX
196
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$344K 0.01%
+250
New +$3.83K
PCYC
197
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$341K 0.01%
29
– –
PLUR icon
198
Pluri
PLUR
$14.4M
$340K 0.01%
1,488
+989
+198% +$225K
IMNN icon
199
Imunon
IMNN
$7.86M
$324K 0.01%
40
-15
-27% -$131K
SGYPW
200
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$321K 0.01%
386,391
-3,591
-0.9% -$4.37K
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.